Engineering the gut microbiota to treat hyperammonemia

Journal of Clinical Investigation

Volumn 125, Issue 7, 2015, Pages 2841-2850

  Shen, Ting Chin David ^a   Albenberg, Lindsey ^b   Bittinger, Kyle ^a   Chehoud, Christel ^a   Chen, Ying Yu ^a   Judge, Colleen A ^b   Chau, Lillian ^a   Ni, Josephine ^a   Sheng, Michael ^a   Lin, Andrew ^a   Wilkins, Benjamin J ^b   Buza, Elizabeth L ^c   Lewis, James D ^a   Daikhin, Yevgeny ^b   Nissim, Ilana ^b   Yudkoff, Marc ^b   Bushman, Frederic D ^a   Wu, Gary D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UREASE; AMMONIA; BACTERIAL PROTEIN;

ACUTE DISEASE; AMMONIA FORMATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BIOLOGICAL THERAPY; CHRONIC DISEASE; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME ACTIVITY; HYPERAMMONEMIA; INOCULATION; INTESTINE FLORA; LIVER INJURY; MICROBIAL COMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHAEDLER FLORA; ANIMAL; BACTERIAL GENE; BACTERIUM; BIOENGINEERING; C57BL MOUSE; DIGESTIVE SYSTEM; DISEASE MODEL; DRUG-INDUCED LIVER INJURY; ENZYMOLOGY; FECES; FEMALE; GENETICS; MALE; METABOLISM; MICROBIOLOGY; MICROFLORA; PHYSIOLOGY; PROCEDURES; SCID MOUSE; TIME;

AMMONIA; ANIMALS; BACTERIA; BACTERIAL PROTEINS; BIOENGINEERING; BIOLOGICAL THERAPY; DIGESTIVE SYSTEM; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; FECES; FEMALE; GENES, BACTERIAL; HYPERAMMONEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; MICROBIOTA; TIME FACTORS; UREASE;

EID: 84936818109     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI79214     Document Type: Article

References (61)

1. Backhed F, et al. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe. 2012;12(5):611-622.
2. Lemon KP, Armitage GC, Relman DA, Fischbach MA. Microbiota-targeted therapies: an ecological perspective. Sci Transl Med. 2012;4(137):137rv135.
3. van Nood E, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-415.
4. Lawley TD, et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 2012;8(10):e1002995.
5. Walser M, Bodenlos LJ. Urea metabolism in man. J Clin Invest. 1959;38:1617-1626.
6. Mobley HL, Hausinger RP. Microbial ureases: significance, regulation, and molecular characterization. Microbiol Rev. 1989;53(1):85-108.
7. Saudubray JM, Nassogne MC, de Lonlay P, Touati G. Clinical approach to inherited metabolic disorders in neonates: an overview. Semin Neonatol. 2002;7(1):3-15.
8. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med. 1997;337(7):473-479.
9. Leitman P. Liver disease, aminoglycoside antibiotics and renal dysfunction. Hepatology. 1988;8(4):966-968.
10. Hampel H, Bynum G, Zamora E, El-Serag H. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol. 2001;96(7):2206-2210.
11. Bass N, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081.
12. Mullen K, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014;12(8):1390-1397.
13. Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther. 2010;31(9):1012-1017.
14. Nicaise C, et al. Control of acute, chronic, and constitutive hyperammonemia by wild-type and genetically engineered Lactobacillus plantarum in rodents. Hepatology. 2008;48(4):1184-1192.
15. McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011;(11):CD008716.
16. Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: A randomized controlled trial. Clin Gastroenterol Hepatol. 2014;12(6):1003-1008.e1001.
17. Dewhirst FE, et al. Phylogeny of the defined murine microbiota: altered Schaedler flora. Appl Environ Microbiol. 1999;65(8):3287-3292.
18. Geuking MB, et al. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity. 2011;34(5):794-806.
19. Willing BP, Vacharaksa A, Croxen M, Thanachayanont T, Finlay BB. Altering host resistance to infections through microbial transplantation. PLoS One. 2011;6(10):e26988.
20. Manichanh C, et al. Reshaping the gut microbiome with bacterial transplantation and antibiotic intake. Genome Res. 2010;20(10):1411-1419.
21. Wannemuehler MJ, Overstreet AM, Ward DV, Phillips GJ. Draft genome sequences of the altered schaedler flora, a defined bacterial community from gnotobiotic mice. Genome Announc. 2014;2(2):e00287-14.
22. Dollive S, et al. Fungi of the murine gut: episodic variation and proliferation during antibiotic treatment. PLoS One. 2013;8(8):e71806.
23. Hill DA, et al. Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with associated alterations in immune cell homeostasis. Mucosal Immunol. 2010;3(2):148-158.
24. Arumugam M, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174-180.
25. Hildebrandt MA, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 2009;137(5):1716-1724 e1711.
26. Singh R. Nutritional management of patients with urea cycle disorders. J Inherit Metab Dis. 2007;30(6):880-887.
27. Alexander T, Thomas K, Cherian A. Effect of three antibacterial drugs in lowering blood & stool ammonia production in hepatic encephalopathy. Indian J Med Res. 1992;96:292-296.
28. Zhao H, Wang H, Lu Z, Xu S. Intestinal microflora in patients with liver cirrhosis. Chin J Dig Dis. 2004;5(2):64-67.
29. James J, Ziparo V, Jeppsson B, Fischer J. Hyperammonaemia, plasma aminoacid imbalance, and blood-brain aminoacid transport: A unified theory of portal-systemic encephalopathy. Lancet. 1979;2(8146):772.
30. Fischer J, Baldessarini R. False neurotransmitters and hepatic failure. Lancet. 1971;2(7715):75-80.
31. Holecek M. Ammonia and amino acid profiles in liver cirrhosis: effects of variables leading to hepatic encephalopathy. Nutrition. 2015;31(1):14-20.
32. Miranda AS, et al. A thioacetamide-induced hepatic encephalopathy model in C57BL/6 mice: A behavioral and neurochemical study. Arq Neuropsiquiatr. 2010;68(4):597-602.
33. Ishikawa S, et al. CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice. J Hepatol. 2011;54(6):1195-1204.
34. Elinav E, et al. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function. Hepatology. 2009;49(1):278-286.
35. Avraham Y, et al. Cannabidiol improves brain and liver function in a fulminant hepatic failureinduced model of hepatic encephalopathy in mice. Br J Pharmacol. 2011;162(7):1650-1658.
36. Hughes RN. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci Biobehav Rev. 2004;28(5):497-505.
37. Hecht GA, et al. What is the value of a food and drug administration investigational new drug for fecal microbiota transplantation in Clostridium difficile infection? Clin Gastroenterol Hepatol. 2014;12(2):289-291.
38. Dominguez-Bello MG, Blaser MJ, Ley RE, Knight R. Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology. 2011;140(6):1713-1719.
39. Albenberg L, et al. Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota in humans and mice. Gastroenterology. 2014;147(5):1055-63.e8.
40. Human Microbiome Project Consortium. Structure, function diversity of the healthy human microbiome. Nature. 2012;486(7402):207-214.
41. Qin J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65.
42. Momose Y, Park SH, Miyamoto Y, Itoh K. Design of species-specific oligonucleotide probes for the detection of Bacteroides and Parabacteroides by fluorescence in situ hybridization and their application to the analysis of mouse caecal Bacteroides-Parabacteroides microbiota. J Appl Microbiol. 2011;111(1):176-184.
43. Sakamoto M, Benno Y. Reclassification of Bacteroides distasonis, Bacteroides goldsteinii and Bacteroides merdae as Parabacteroides distasonis gen. nov., comb. nov., Parabacteroides goldsteinii comb. nov. and Parabacteroides merdae comb. nov. Int J Syst Evol Microbiol. 2006;56(Pt 7):1599-1605.
44. Smith MI, et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science. 2013;339(6119):548-554.
45. Faust K, et al. Microbial co-occurrence relationships in the human microbiome. PLoS Comput Biol. 2012;8(7):e1002606.
46. Wu GD, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105-108.
47. Freter R, Stauffer E, Cleven D, Holdeman LV, Moore WE. Continuous-flow cultures as in vitro models of the ecology of large intestinal flora. Infect Immun. 1983;39(2):666-675.
48. Lee SM, Donaldson GP, Mikulski Z, Boyajian S, Ley K, Mazmanian SK. Bacterial colonization factors control specificity and stability of the gut microbiota. Nature. 2013;501(7467):426-429.
49. Eckburg PB, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635-1638.
50. Fischbach MA, Sonnenburg JL. Eating for two: how metabolism establishes interspecies interactions in the gut. Cell Host Microbe. 2011;10(4):336-347.
51. Torrallardona D, Harris C, Coates M, Fuller M. Microbial amino acid synthesis and utilization in rats: incorporation of 15N from 15NH4Cl into lysine in the tissues of germ-free conventional rats. Br J Nutr. 1996;75(5):689-700.
52. Belenguer A, Balcells J, Guada J, Decoux M, Milne E. Protein recycling in growing rabbits: contribution of microbial lysine to amino acid metabolism. Br J Nutr. 2005;94(5):763-770.
53. Metges C, et al. Incorporation of urea and ammonia nitrogen into ileal and fecal microbial proteins and plasma free amino acids in normal men and ileostomates. Am J Clin Nutr. 1999;70(6):1046-1058.
54. Bustamante J, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30(5):890-895.
55. Wu GD, et al. Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol. 2010;10:206.
56. Hoffmann C, et al. DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic acids research. 2007;35(13):e91.
57. Hamady M, Walker JJ, Harris JK, Gold NJ, Knight R. Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex. Nature methods. 2008;5(3):235-237.
58. Caporaso JG, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7(5):335-336.
59. Tuchman M, et al. N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr Res. 2008;64(2):213-217.
60. Lalonde R. The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev. 2002;26(1):91-104.
61. Lozupone C, Knight R. UniFrac: A new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005;71(12):8228-8235.